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Background: In a previous study we observed an increasing trend in candidemia in Finland in the 1990s. Our aim
was now to investigate further population-based secular trends, as well as outcome, and evaluate the association
of fluconazole consumption and prophylaxis policy with the observed findings.
Methods: We analyzed laboratory-based surveillance data on candidemia from the National Infectious Diseases
Register during 2004-2007 in Finland. Data on fluconazole consumption, expressed as defined daily doses, DDDs,
was obtained from the National Agency for Medicines, and regional prophylaxis policies were assessed by a
telephone survey.
Results: A total of 603 candidemia cases were identified. The average annual incidence rate was 2.86 cases per
100,000 population (range by year, 2.59-3.09; range by region, 2.37-3.85). The highest incidence was detected in
males aged >65 years (12.23 per 100,000 population). Candida albicans accounted for 67% of cases, and C. glabrata
ranked the second (19%), both without any significant change in proportions. C. parapsilosis accounted for 5% of
cases and C. krusei 3% of cases. The one-month case-fatality varied between 28-32% during the study period.
Fluconazole consumption increased from 19.57 DDDs per 100,000 population in 2000 to 25.09 in 2007. Systematic
fluconazole prophylaxis was implemented for premature neonates, patients with acute leukemias and liver
transplant patients.
Conclusion: The dominant proportion of C. albicans remained stable, but C. glabrata was the most frequent non-
albicans species. The proportion of C. glabrata had increased from our previous study period in the presence of
increasing use of fluconazole. The rate of candidemia in Finland is still low but mortality high like in other
countries.
Background
Bloodstream infections caused by Candida spp. repre-
sent a considerable burden in hospitalized patients and
are associated with high mortality and an excess length
of stay [1-5]. Candida is an important cause of blood-
stream infections worldwide. In the USA Candida spe-
cies rank the fourth most common (7-9%) causative
organism of all bloodstream infections in hospitalized
patients,[6-8] but in Europe it accounts for less than 5%
[9-11].
Despite the considerable burden from candidemia in
hospitalized patients, most population-based studies are
from the USA [12-15]. The reported population-based
incidences of candidemia have increased over the past
two decades, though this varies between countries and
the time periods in many analyses are relatively short
[12-19]. Population-based analyses avoid the selection
bias associated with single institutions or tertiary care
centers allowing calculations of incidence and mortality
rates. The reasons for the increasing candidemia rates
include improved detection as well as increase in
patient-population at risk, as invasive procedures and
devices, broad-spectrum antimicrobial agents, advanced
life-support and aggressive chemotherapy are more
extensively used.
A shift towards non-albicans species has been reported
previously from the USA, Europe and Australia, although
the precise pattern of causative species varies across
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portion of non-albicans species, especially C. glabrata,
[10,12,16,20,22,23,26,28] has aroused concern due to its
tendency toward decreased susceptibility to fluconazole.
Previously, we reported a low, but increasing incidence
of candidemia during 1995-1999 in Finland [29]. Our
present study reports the trends in incidence rates of
candidemia in Finland from 2004 to 2007, using data on
bloodstream infections from laboratory-based nation-
wide surveillance. We also analyzed fluconazole con-
sumption during 2000-2007, and assessed the policy of




In Finland (population 5.3 million), the national health
care system is organized into 5 geographically and
administratively defined tertiary care districts, with
populations ranging from 0.72-1.76 million.
Since 1995, all clinical microbiology laboratories in
Finland have notified all bacterial and fungal isolations
from blood, including Candida species, to the National
Infectious Diseases Register maintained by the National
Institute of Health and Welfare. Detection and species
identification of Candida isolates are performed in the
notifying laboratories according to standard protocols in
use in each laboratory. Data collected with each notifi-
cation include the date of isolation, the date of birth,
sex, the type of specimen, and the place of treatment. A
case of candidemia was defined as a patient with at
least one blood culture positive for Candida species.
Notifications of the same species of Candida within 3
months from the first diagnostic sample in the same
person were defined as one case. Isolation of the same
species beyond this time period was defined as a sepa-
rate case.
Consumption of fluconazole
Data on fluconazole consumption in defined daily doses,
DDDs, during 2000-2007 was obtained from the
National Agency for Medicines.
Survey on prophylactic policy
We interviewed infectious diseases specialists in the five
tertiary care hospitals per telephone using a structured
questionnaire about written guidelines or routine prac-
tice for fluconazole prophylaxis in their hospital among
following patient groups, adults (≥15 years) and children
(<15 years) separately: patients with hematologic or
other malignancy, patients treated in intensive care, sur-
gical patients, organ transplant patients and premature
neonates.
Calculation of incidence rates and statistical analysis
Using the patients’ unique national identity number for
register linkage, individual death data were acquired for
the period 2004-2007 from the National Population
Information System for determining survival at 28 days
from the first positive blood culture. Denominators to
calculate age- and sex-specific incidence rates were
acquired from the same register. The average annual
incidences during the surveillance period were calcu-
lated by using the total number of cases and population
during 2004-2007. To evaluate secular trends, rates of
candidemia cases in different age and sex groups were
calculated for each 12-monthp e r i o df r o mJ a n u a r y2 0 0 4
to December 2007. Poisson regression model was used
to assess whether the observed changes in the rates or
fluconazole consumption were statistically significant.
Categorical variables were analyzed with the c
2 test,
using Yates`s correction, or Fisher`s exact test, as appro-
priate. Continuous variables were analyzed by Student`s
t test or by the Mann-Whitney U test, depending on the
s a m p l ed i s t r i b u t i o n .D a t aw e r ea n a l y z e db yS P S Sf o r
Windows version 11 (Chicago, USA).
Data approval
The data of National Infectious Diseases Register is pub-
licly available in annual reports of National Institute of
Health and Welfare, although not as detailed form as in
our study. The data of fluconazole consumption is pub-
licly available in annual reports of National Agency for
Medicines. The detailed analysis prepared in our study
was authorized by these both authorities holding the ori-
ginal data. The data for calculations from the National
Population Information System for years 2004-2007 was
authorized by National Institute of Health and Welfare in
connection with National Infectious Diseases Register.
Results
Demographics and incidence
A total of 603 candidemia cases were reported to NIDR
during 2004-2007. The median age of the case-patients
was 64 years (range, 0-94 years,) and 337 (56%) were
males. The average annual incidence of candidemia was
2.86 cases per 100,000 population (range by year, 2.59-
3.09 per 100,000) without any trend during the study
period.
The average annual incidence was significantly higher
in males than in females, especially among patients >65
years of age (Table 1). The highest average annual inci-
dence was observed in males >65 years of age, and low-
est in males 1-15 years of age. Only in males 16-65
years of age the annual rate slightly increased during the
study period, from 2.11 to 2.65 per 100,000 population,
but the trend was not statistically significant.
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2.37-3.85 per 100,000 population in the five tertiary care
districts; the incidence increased in three districts, but
the trends were not statistically significant (Table 2).
The highest annual incidence rate was observed in Oulu
in 2006, and the lowest in Helsinki in 2005.
Causative species
Candida albicans was the most frequent species
encountered, causing 406 (67%) cases and C. glabrata
ranked second (19%), followed by C. parapsilosis (5%),
C. krusei (3%), and C. tropicalis (2%) (Figure 1). The
other species reported were C. lusitaniae, C. guillier-
mondii and C. dubliniensis; two species were reported
in 7 (1%) cases, and in 4 (1%) cases the Candida species
was unknown. During the study period, the proportions
of C. glabrata and non-albicans species overall did not
increase. Among the five tertiary care districts, the pro-
portion of non-albicans species peaked during 2004-
2005 in Turku at 44-42% and 2004 in Tampere at 42%,
mainly consisting of C. glabrata and C. parapsilosis
(Table 2). Thereafter, the proportion of non-albicans
species remained lower (range, 18-36%) in all districts.
Mortality
Data on outcome was available for 598 (99%) case-
patients, 208 (35%; range by year, 32-38%, and range by
district, 31-37%) of whom died within one month after
the onset of candidemia. The average annual mortality
rate was 0.99 deaths per 100,000 population (range by
year, 0.89-1.08, and range by district, 0.91-1.27). The
case-patients who died were significantly older than
those who survived (median age, 70 vs 62 years; P <
0.01).
Fluconazole consumption
Fluconazole consumption increased significantly from
19.57 DDDs per 100,000 population in 2000 to 25.09 in
2007 (P < 0.01) (Figure 2). The increase in consumption
was statistically significant in all five regions (P < 0.01).
Per oral consumption covered 89% (range by year, 88-
90%) of the total fluconazole use, the rest was parental
use.
Prophylactic policies
Fluconazole prophylaxis was used in all five tertiary
care centers for adult acute leukemia patients treated
with intensive chemotherapy, over each period of neu-
tropenia, mostly from 2000 on and in one center since
2007. Written guidelines were in place in three of
these centers. Pediatric patients with acute myeloid
leukemia were on fluconazole prophylaxis during neu-
tropenia caused by intensive chemotherapy in four out
of the five centers since 1998-2000 on (written guide-
lines existed in three); patients with acute lymphatic
leukemia were administered fluconazole prophylaxis
during neutropenia in two centers (written guideline
existed in one).
Table 1 Incidence of candidemia by age and sex, Finland 2004-2007.
Age group (y) Male Female All Rate ratio** Confidence interval (95%)
Number of cases Rate Number of cases Rate Number of cases Rate*
<1 11 9.24 5 4.39 16 6.87 2.1 0.36-4.13
1-15 1 0.05 8 0.45 9 0.25 0.12 0.03-0.89
16-65 169 2.39 126 1.82 295 2.11 1.31 1.04-1.67
>65 156 12.23 127 6.57 283 8.82 1.86 1.46-2.37
All 337 3.27 266 2.47 603 2.86 1.32 1.12-1.56
*Average incidence during the study period (per 100,000 population).
**Male to female rate ratio.
Table 2 Candidemia incidence and proportion of non-albicans species by tertiary care center districts, Finland 2004-
2007.
Incidence of candidemia, cases per 100,000 population
(Proportion of non-albicans species, %)
Region (population) 2004 2005 2006 2007 2004-2007
Helsinki (1.76 million) 2.92 (41) 1.82 (22) 2.32 (24) 2.69 (33) 2.44 (31)
Tampere (1.2 million) 3.00 (25) 2.74 (42) 3.64 (21) 3.45 (36) 3.21 (30)
Turku (0.72 million) 2.24 (44) 2.66 (42) 3.07 (27) 3.63 (35) 2.9 (36)
Oulu (0.73 million) 3.31 (30) 3.58 (38) 4.54 (36) 3.98 (18) 3.85 (30)
Kuopio (0.85 million) 2.34 (20) 3.05 (27) 1.88 (31) 2.23 (26) 2.37 (26)
All 5 regions (5.2 million) 2.81 (33) 2.59 (34) 2.96 (27) 3.09 (30) 2.86 (31)
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stem cell recipients in one center out of five according
to a written guideline since 2007. Pediatric autologic
stem cell recipients were on fluconazole prophylaxis in
four out the five centers during hospital stay or neutro-
penia mostly since 2000 on (written guideline existed in
two centers).
Allogenic stem cell transplantations for pediatric
patients were performed only in three tertiary care cen-
ters for all regions and fluconazole prophylaxis was
administered according to a written guideline in all three
centers for at least during hospital stay and in one center
for 6 months since 2000 on. Solid organ transplantations
were performed solely in one tertiary care center for all
regions. Only liver transplantation patients (adults and
children) were on fluconazole prophylaxis starting right
before or at the operation and lasting at least 5 days post-
operatively from 1998 on, without written guidelines.
Premature infants received fluconazole prophylaxis
usually for 2-6 weeks or during invasive monitoring in
Figure 1 Distribution of Candida species by region (tertiary-care center catchment area), Finland 2004-2007.
Figure 2 Use of fluconazole in daily defined doses (DDD) by region (tertiary-care center catchment area) in Finland, 2000-2007.
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Page 4 of 7four out of the five tertiary care centers; written guide-
lines existed in two. Prophylaxis was used at least since
2002-2004 on in all four centers. No guidelines for flu-
conazole prophylaxis to adult or pediatric intensive care
patients or surgical patients were in place in any tertiary
care center.
Discussion
Our population-based study shows that the incidence of
candidemia in Finland was low and stable during 2004-
2007 in the face of increased fluconazole consumption.
C. glabrata ranked second to C. albicans in proportion,
but the proportion of non-albicans species did not
increase.
Compared with our previous nationwide population-
based data from Finland during 1995-1999, the average
annual incidence of candidemia has increased markedly
from 1.9[29] to 2.86 per 100,000 population in the cur-
rent study period. The rate in Finland is only approxi-
mately one third of the rates reported from the USA,
most reports ranging between 6-10 per 100,000 popula-
tion, while a considerably higher incidence of 24 per
100,000 population has been reported from the city of
Baltimore [12-15]. Low incidence rates of 2.4-2.8 per
100,000 population have also been reported from
Norway and Canada,[19,30] while incidences have been
somewhat higher elsewhere in Europe,[18,31] and con-
siderable higher (10.4 per 100,000 population) in
Denmark [16]. Extended surveillance periods have been
previously reported from Iceland for 1980-2006, and
from Norway for 1991-2003; the incidences increased
from 1.4 to 5.8 and from 2 to 3 per 100,000 population,
respectively [17-19]. Thus, the increasing rate in Finland
between the periods in the 1990s and the 2000s high-
lights the growing importance of Candida spp. in hospi-
talized patients. The marked differences in candidemia
rates between countries may reflect differences in repre-
sentativeness and age distributions of the study popula-
tions, variations in health care practices, patterns using
blood cultures, and antibiotic usage as well as the resis-
tance situation.
The male dominance we observed during 2004-2007 is
in accordance with our previous study from years 1995-
1999, and with most reports both from USA and Eur-
ope,[12,14,16,19,29] but in contrast with some others
[13,30]. By age and sex, the incidence rates increased
most in patients >65 years of age, from 5.2 during 1995-
1999[29] to 8.82 per 100,000 population in the current
study, particularly in males, being in the same range as
in Norway and Spain,[19,31] but clearly lower than in
Denmark, Iceland and USA (19.3-36.9 per 100,000
population) [14,16,17]. Interestingly, in the two youngest
age groups (<1 year and 1-15 years of age), the inci-
dence was lower during 2004-2007 than during 1995-
1999 in Finland. This is partly explained by fading of an
outbreak of C. parapsilosis in the neonatal intensive
care unit of Helsinki University Hospital from 2002 on
[32]. Incidence rates in infants <1 year of age have been
clearly higher, 20-75 per 100,000 population, in North-
ern America and Spain,[14,30,31] and somewhat higher
in other Nordic countries, 10.3-16.3 per 100,000 popula-
tion, than in Finland [16,17,19].
We did not observe any changes in the proportion of C.
albicans between 1990s[29] and 2000s (current study) in
Finland, but the proportion of C. glabrata increased con-
siderably from 9% to 19%. Other Candida species were
isolated only rarely, and between the study periods, the
proportion of C. krusei decreased from 8% to 3%. The
reason for this decrease is elusive, and is not explained by
sheer antibiotic pressure, but may associate with patient
demographics or underlying conditions. The stable pre-
dominance of C. albicans we have observed is in contrast
to several reports from the USA and Europe, in which
the proportion of non-albicans species has increased up
to 40-50% [10,12-14,18,20,22-27,33]. However, no shift to
non-albicans species was detected in Norway, Iceland,
Belgium and Switzerland [17,19,34-36]. The increase in
C. glabrata has previously been reported from the USA,
[12,20,22-24,26] and from Europe [10,16,28]. The reasons
for the increasing proportion of C. glabrata may include
exposure to azoles or antibacterial agents, differences in
patient age, comorbidities and in blood culture systems
to isolate Candida spp.
The total consumption of fluconazole increased in all
five regions in Finland during 2000-2007, which suggests
also increased usage of fluconazole in tertiary care hos-
pitals. Previously, we reported high fluconazole con-
sumption in one tertiary care center in Finland,
reaching 135 grams per 10,000 patient-days (corre-
sponding to 6750 DDDs per 100,000 patient days) in
2004,[37] in the same range with consumption of 5013-
6807 DDDs per 100,000 patient-days during 1994-2004
in Belgium [34]. From earlier time periods, clearly lower
fluconazole consumption was reported from a multicen-
ter study in Switzerland, with 30 grams per 10,000
patient-days (corresponding to 1500 DDDs per 100,000
patient-days) in 2000 [36] and in the USA, with >30
grams per 10,000 patient days in 1993 [38].
Prophylaxis with fluconazole was systematically used
during our current study period in patients with acute
leukemias, liver transplant patients, and in premature
infants. The prophylactic use of fluconazole in neonates
and pediatric leukemia patients may have contributed to
the observed decreasing rates of candidemia in patients
<16 years. Despite the increase in fluconazole consump-
tion during 2000s, we did not observe any shift towards
non-albicans species as a whole, but among non-albicans
species the proportion of C. glabrata increased during
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Page 5 of 72004-2007 compared to our previous study [29]. The role
of fluconazole consumption in the shift of causative Can-
dida species is inconclusive, as several reports have
observed the effect[20,23,26], while others have not
[19,24,34,36].
The one-month case fatality proportion remained stable
at 35% over the study period, and was associated with
advanced age, like in our previous study from years 1995-
1999 [29]. This is in line with most earlier reports from
the USA and Europe,[3,13,25,28] although higher rates 44-
45% have been reported from some centers [27,33].
Our study has several limitations. This is an ecologic
study in which we used the total consumption data on
fluconazole in different tertiary-care catchment regions,
in connection with our population-based data of inci-
dence rates, making inferences on individual patients
based on average population statistics. With only labora-
tory-based reporting, it is not possible to differentiate
between nosocomial and community-onset infection.
Consequently, we could not calculate fluconazole con-
sumption as DDDs pe patient-days. In our previous study
from one tertiary care center during 1987-2004 the pro-
portion of non-nosocomial infections was 4% [37], but
we do not know what proportion of our present data
represents of nosocomial candidemias. We do not have
data on sensitivity to fluconazole. Guidelines and routine
prophylaxis policies presented are limited to patients in
tertiary care centers, and thus affect the candidemia rates
in these hospitals, and not on health-care institutions as
a whole. However, the infectious diseases physicians of
the centers have a key consulting role in their districts on
policies regarding high risk groups for candidemia.
Conclusions
Our study demonstrates that candidemia has increased
in Finland between 1990s and 2000s, although the inci-
dence still remains internationally low. Fluconazole pro-
phylaxis in hematological patients and neonates is
systematically implemented, while no systematic prophy-
laxis is used in the intensive care setting. The increasing
proportion of C. glabrata is of concern, but this increase
may be caused by other risk-factors than increasing flu-
conazole usage. The high case-fatality emphasizes the
need for continuing surveillance to optimize prevention
policies, including antifungal prophylaxis.
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